Tranylcypromine/trifluoperazine

Tranylcypromine/trifluoperaizne
Combination of
Tranylcypromine Monoamine oxidase inhibitor
Trifluoperazine Typical antipsychotic
Clinical data
Trade names Parstelin, Parmodalin, Jatrosom N, Stelapar
Routes of
administration		 Oral
Legal status
Legal status
  • ℞ (Prescription only)

Tranylcypromine/trifluoperazine (brand names Parstelin, Parmodalin, Jatrosom N, Stelapar) is a combination formulation of the monoamine oxidase inhibitor antidepressant drug tranylcypromine and the typical antipsychotic drug trifluoperazine that has been used in the treatment of major depressive disorder.[1][2][3] It contains 10 mg tranylcypromine and 1 mg trifluoperazine.[3][4] The drug has been in clinical use since at least 1961.[3] It is still available in Italy with the name of Parmodalin[5].

See also

References

  1. ↑ Richard C. Dart (2004). Medical Toxicology. Lippincott Williams & Wilkins. pp. 825–. ISBN 978-0-7817-2845-4.
  2. ↑ Stephen M. Stahl (15 May 2014). Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. pp. 783–. ISBN 978-1-107-67502-5.
  3. 1 2 3 Straker M, Grauer H (1961). "Clinical Study of a Potent Antidepressant, Tranylcypromine with Trifluorperazine (Parstelin ), in the Aged Chronically Ill". Can Med Assoc J 85 (3): 127–30. PMC 1848140. PMID 20326829.
  4. ↑ Lothar Bruno Kalinowsky; Hanns Hippius; Helmfried E. Klein (1982). Biological Treatments in Psychiatry. Grune and Stratton, Harcourt Brace Jovanovich. ISBN 978-0-8089-1423-5.
  5. ↑ "SIT - Parmodalin". www.sit-farmaceutici.com. Retrieved 2016-04-18.


This article is issued from Wikipedia - version of the Monday, April 18, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.